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Abstract: Febrile neutropenia (FN) is a frequent complication of cancer treatment in 
children. Owing to the potential for overwhelming bacterial sepsis, the recognition and 
management of FN requires rapid implementation of evidenced-based management proto-
cols. Treatment paradigms have progressed from hospitalisation with broad spectrum anti-
biotics for all patients, through to risk adapted approaches to management. Such risk adapted 
approaches aim to provide safe care through incorporating antimicrobial stewardship (AMS) 
principles such as implementation of comprehensive clinical pathways incorporating de- 
escalation strategies with the imperative to reduce hospital stay and antibiotic exposure 
where possible in order to improve patient experience, reduce costs and diminish the risk 
of nosocomial infection. This review summarises the principles of risk stratification in FN, 
the current key considerations for optimising empiric antimicrobial selection including 
knowledge of antimicrobial resistance patterns and emerging technologies for rapid diagnosis 
of specific infections and summarises existing evidence on time to treatment, investigations 
required and duration of treatment. To aid treating physicians we suggest the key features 
based on current evidence that should be part of any FN management guideline and highlight 
areas for future research. The focus is on treatment of bacterial infections although fungal 
and viral infections are also important in this patient group. 
Keywords: paediatric, febrile neutropenia, antimicrobials
Plain Language Summary
Children undergoing treatment for cancer are at risk of serious infections which may be seen 
as a fever with a low white blood cell count (neutropenia). This condition is called febrile 
neutropenia (FN). The treatment of FN has changed over time. In the past all patients were 
treated in hospital with antibiotics that cover a range of infections. Now, treatment depends 
on the chance that an individual child has a serious infection. This means for some children 
we can reduce the time spent in hospital and use fewer antibiotics. This article describes the 
research behind current best practice in the treatment of FN in children. We focus on:
● Recognising FN quickly.
● Starting treatment rapidly.
● Which antibiotics to use.
● How long to give them for.
We suggest the things that all health care workers should think about when treating children 
with FN and what further research is needed to improve care in the future.
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Introduction
Fever with neutropenia (febrile neutropenia; FN) is one of 
the commonest complications in the treatment of child-
hood cancer and is a significant cause of hospitalisation 
with attendant disruption to the child and family, risks of 
nosocomial infection and associated healthcare costs. 
Bacteraemia is identified in 11–24% of children with FN 
and intensive care admission is reported in up to 11% of 
episodes with mortality rates of up to 3%.1 Overall gram 
positive organisms tend to be identified in blood cultures 
slightly more commonly than gram negative organisms, 
however this ratio is influenced by the timing of blood 
cultures (i.e pre or post antibiotic), presence of central 
lines and concurrent antibacterial prophylaxis.2,3 In 
a large series of FN episodes in children with cancer, 
59% of children had no documented clinical or microbio-
logical evidence of infection, 24% had bacteraemia, 2% 
had a microbiologically documented infection without 
bacteraemia, 6% had a clinically documented infection 
and 9% had a fungal infection.4
Owing to the risk of bacteraemia, FN is traditionally 
managed by urgent hospital attendance and empirical 
broad spectrum intravenous antibiotics until resolution of 
fever with average inpatient stay reported as 5 days across 
many UK and Australian paediatric oncology settings.5–8 
However, it has become apparent in recent years that FN 
episodes are heterogenous; the risk of significant infection 
varies among different patients and episodes and the 
approach of hospitalising all patients until resolution of 
fever and recovery of neutrophil count overtreats 
a significant group of lower risk patients, increasing hos-
pital stay and costs and risking evolution of antimicrobial 
resistance. Current international guidance now recom-
mends a risk-stratified approach to treatment of paediatric 
FN with the aim of improving patient experience and 
practising responsible antimicrobial stewardship (AMS) 
by limiting unnecessary or prolonged antibiotics in care-
fully selected patients.9
This article is focused on improving detection and 
optimising antibacterial management of FN and highlights 
recent literature in this area. An updated paediatric specific 
FN guideline is available elsewhere.9,10 Fungal and viral 
infections and their treatment will not be considered in 
detail and non-neutropenic fever is reviewed 
elsewhere.11,12 We will discuss optimising antimicrobial 
selection, reducing hospital stay, the role of biomarkers to 
predict infection risk and the role of new rapid diagnostic 
techniques. Many of the recommendations we discuss are 
informed by data from studies in high-income countries. 
Clinicians working in low and middle-income countries 
may need to consider other factors such as the prevalence 
of other specific infections (including malaria and other 
parasites), the availability of diagnostic testing, patient 
access to healthcare (including transport options), nutri-
tional status of the population, the intensity of chemother-
apy regimes delivered (with their associated infection 
risks), antibiotic resistance patterns and availability of 
specific antimicrobial medicines when planning effective 
FN management pathways.13
Diagnosis and Initial Investigation of 
FN
Optimal management of FN requires consistent, evidence- 
based, definitions of the condition. No international con-
sensus exists on the definitions of fever and neutropenia 
although common definitions of fever include >38 °C, 
>38.3 °C, or >38.5 °C, and for neutropenia are <0.5 
x109/L or <1.0 x109/L and expected to fall to <0.5 x109/ 
L within 48 h.14 Within the UK, the National Institute for 
Health and Care Excellence (NICE) guidelines advise the 
use of a neutrophil count of ≤0.5 x109/L and either a fever 
>38 °C or other signs or symptoms consistent with clini-
cally significant sepsis.15 However, only 64% of UK cen-
tres used this definition in a 2017 audit.16 Furthermore, 
a recent trial conducted in Switzerland has suggested 
that a limit of 39 °C ear temperature is non-inferior to 
38.5 °C.17 Further work is needed to clarify the most 
appropriate definitions of FN, and to facilitate consistency 
of use across the clinical and research community.
Blood cultures remain the gold standard test for diag-
nosis of blood stream infections in FN. While early studies 
found up to 22% of children with FN had a bacteraemia, 
more recent observational data indicate that bacteraemia 
rates may be lower than this and likely explained by the 
exclusion of common commensals unless cultured more 
than once.3 Not surprisingly, the diagnostic yield is highest 
when two or more blood cultures are taken prior to the first 
dose of antibiotics and, in the absence of a new fever or 
clinical instability, blood cultures beyond 48 hours of 
persistent fever have limited diagnostic utility.3 Data 
from a prospective, observational paediatric FN study 
found that almost 75% of blood cultures were positive 
within the first 24 hours of collection. Observational pae-
diatric data also show as many as 17% of true blood 
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stream infections in patients with a central venous catheter 
(CVC) are detected in cultures taken from a peripheral 
vein only, suggesting both CVC and peripheral vein cul-
tures should be collected to optimise diagnosis.18 The 
quality of collection, including number of sets (aerobic 
and anaerobic) taken pre antibiotics and volume of blood 
have also been shown to impact the diagnostic yield of 
blood cultures in the general paediatric population, high-
lighting the importance of specific blood culture collection 
guidelines in FN.19
Rapid diagnostic technologies that expedite pathogen 
identification are, in theory, an important way to improve 
antibiotic use in FN. Despite the availability and use of 
these technologies for infection diagnosis in other areas 
of medicine, few studies have explored the clinical impact 
of these in the FN population.20 Concerns about polymer-
ase chain reaction (PCR) based systems include that the 
panels used may not cover all of the organisms seen in this 
population, the sensitivity of the PCR means tiny amounts 
of bacterial nucleic acids or contamination create noisy 
results and not all antimicrobial resistance can be spotted 
in the circulating DNA.21
There is emerging evidence that PCR based tests for 
respiratory viruses can increase diagnostic accuracy in 
children with FN. In a study of nasopharyngeal samples 
obtained in 1044 episodes of FN in 525 children, multiplex 
PCR testing for 17 respiratory viruses revealed at least 1 
respiratory virus in 46% of cases and respiratory virus as 
the sole pathogen(s) detected in 34% of episodes.22 The 
most common viruses detected were rhinovirus, respira-
tory syncytial virus, parainfluenza, influenza viruses, ade-
novirus and human metapneumovirus. The same 
researchers randomised 176 patients with FN, negative 
bacterial cultures and favourable clinical evolution of 
their illness at 48 h between continuing antibiotics and 
stopping antibiotics in hospital, with no differences in 
duration of fever, days of hospitalisation and bacterial 
infections, no deaths and only one case of sepsis requiring 
intensive care admission in a patient continuing 
antibiotics.23 With further data on safety and efficacy, 
such approaches may make an important contribution to 
AMR in the future.
Data on the role of PCR for detecting blood stream 
infections are more limited. In adult patients with FN, 
multiplex PCR systems reduced time to appropriate anti-
biotics but had limited impact on duration in two studies.24 
In contrast, a randomised trial of BioFire Filmarray 
coupled with a comprehensive AMS program in adult 
patients, including 40% who were immunocompromised, 
did show reductions in both areas.25 While the data for 
rapid, molecular based diagnostics in paediatric FN are 
scant so far, these results highlight the importance of 
both diagnostic and AMS interventions to ensure appro-
priate use of these, often costly, tests.
Biomarkers to predict infection or severity of illness 
have been extensively explored in paediatric FN.1,26,27 
However, while over 40 studies have investigated 
a range of biomarkers, most commonly procalcitonin, 
C-reactive protein and IL-6 and IL-8, very few clinical 
decision rules or risk stratification strategies incorporate 
these. The lack of validation and impact studies, combined 
with cost and availability, may in part explain this.
The role of diagnostic imaging, specifically fluoro-
deoxyglucose positron emission tomography (FDG-PET) 
combined with computed tomography (CT) or magnetic 
resonance imaging (MRI), for investigation of prolonged 
FN is also emerging as a potentially useful tool.28,29 
A retrospective study of children with cancer and pro-
longed or recurrent FN found that, compared to conven-
tional imaging, FDG-PET/CT identified additional sites of 
clinically significant infection/inflammation compared to 
conventional imaging. The study also showed that the 
FDG-PET results had a clinical impact in 80%, leading 
to de-escalation or stopping of antibiotics in many 
patients.30 Routine use of FDG-PET has also been pro-
posed as an adjunct to guiding treatment duration of inva-
sive fungal infection in immunocompromised patients and 
has been shown to be cost-effective in this situation.31,32 
The potential benefits of FDG-PET for prolonged or unex-
plained FN in children, in particular the identification of 
occult infection, needs to be balanced with availability and 
requirement for sedation in some patients.
Principles/Concept of Risk 
Stratification in Paediatric FN
Many groups have generated systems to stratify FN epi-
sodes at presentation, and during treatment, into low- or 
high-risk of infection-related adverse outcomes.33 The 
systems are intended to allow clinicians to alter the inten-
sity, duration and consequently location of empiric ther-
apy, in particular to select patients who are suitable for 
reduced intensity, often home-based, care. The systems 
tend to combine factors derived from the likely depth 
and duration of immunosuppression, episode-related ele-
ments of clinical presentation such as shock or hypoxia, 
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and in the case of those choosing patients for out-of- 
hospital programmes, the patient’s social situation.34,35 
These are integrated to mean those who have received 
conditioning chemotherapy for a hematopoietic stem cell 
transplant, or live far from medical facilities without their 
own transport, or have arrived in hospital in septic shock 
would not be treated as out-patients. Although many risk- 
stratification approaches have been proposed, few of them 
have proven effective in isolation.8 This may be overcome 
by embedding them into FN care pathways and taking 
a systems approach to implementation and evaluation. To 
be useful in practice, clinical decision rules should define 
at least 20% of patients as low risk;8 one study embedding 
clinical risk stratification into FN care pathways identified 
27% of patients as “low risk”.36 Other groups are conduct-
ing trials to determine if a biomarker-led approach may be 
even more effective than the clinically based 
stratification.37
Optimising Antimicrobial Selection
Empiric Antibiotics
The choice of empirical antibacterial agents is derived from 
a knowledge of the expected incidence of particular bac-
teria, in part driven by risk stratification, the consequence of 
infection, and their likely antibacterial resistance.38 Gram 
positive organisms are identified in blood cultures more 
commonly than gram negative organisms (58% vs 42%): 
the commonest pathogens identified are coagulase negative 
staphylococci (23%), Enterobacteriaceae (23%), viridans 
streptococci (13%) and Pseudomonas aeruginosa (9%).39 
In most countries, there has been a historical evolution 
through intravenous dual-therapy (with an aminoglycoside) 
to stratified single-agent treatment with an intravenous anti-
pseudomonal agent in those at higher risk of serious infec-
tion, and oral therapy with an antipseudomonal 
fluoroquinolone with or without a penicillin in those at 
lower risk of infection. This has been guided by many 
randomised clinical trials as agents have been introduced 
to the market, mostly in adult and all-age populations, and 
trials driven by the development of stratification systems 
which promote reduced intensity therapy in the low-risk 
groups.9,15,40
The “best guess” antibacterial therapies are then mod-
ified in the light of the developing clinical picture. Such 
changes have historically included planned progressive 
therapy; such as the addition of a glycopeptide if fever 
continues beyond 2–3 days. Clinical trials have 
demonstrated the lack of value of this,41–43 but the practice 
continues and highlights the need for robust AMS inter-
ventions such as pre-authorisations and implementation of 
clinical pathways encompassing the entire FN journey 
coupled with clinical audit and feedback.41–43 These inter-
ventions are critical as the increase in antimicrobial resis-
tance (AMR) worldwide threatens the success of 
traditional empiric FN antibiotic choices. An international 
study across 15 paediatric cancer centres in eight countries 
found high rates of piperacillin-tazobactam resistance 
among some important Gram-negative pathogens includ-
ing, Escherichia coli, Klebsiella pneumoniae and 
P. aeruginosa.44 As the incidence of AMR will vary 
between hospitals and even individual departments, 
empiric FN choices should be informed by local antibio-
grams in consultation with microbiology and infectious 
diseases specialists. In studies of children with cancer, 
independent risk factors for AMR include prior antibiotic 
exposure and hospitalisation and AMR infections are asso-
ciated with adverse outcomes including ICU admission, 
prolonged hospitalisation and death.45,46 For patients tra-
velling from overseas for treatment, the incidence of AMR 
at the sending centre may be unknown and the potential 
for AMR may be a particular consideration. To combat 
these concerns, diagnostic and AMS principles should be 
embedded within FN guidelines to ensure the right inves-
tigations are done and interpretation of these inform the 
right antibiotic choice and duration.47,48 Comprehensive 
and collaborative AMS interventions have been shown to 
reduce antibiotic exposure in immunocompromised 
patients without compromising patient safety and are 
vital to limiting the impact of AMR.47,49–51
Timing of Antibiotics
As well as choice of antibiotics, the time to administration 
(TTA) of empirical antibiotics is expected to influence the 
outcome for patients with bacteraemia or sepsis. Within 
existing research, TTA is most commonly defined as time 
from arrival in hospital to administration of antibiotics 
although in some studies is defined as onset of fever to 
antibiotic administration.52 Adult FN guidelines in Europe 
and America advocate a TTA of <1 hour; most paediatric 
guidelines are not specific on this point but a time of 
<1 hour is generally considered as good practice among 
treating physicians.53,54 A systematic review of TTA in 
adult and paediatric FN episodes was suggestive of an 
increased risk of death, intensive care admission and sep-
sis with a longer TTA but triage bias (in which patients 
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who are more unwell receive faster treatment) was 
noted.52 Despite this lack of precise evidence, TTA is 
considered a measure of quality of care in paediatric FN 
and a number of different, successful approaches to reduce 
TTA have been described.55 These include staff training 
interventions, guidelines, checklists and treatment 
algorithms.56
Viral and Fungal Infections
As in many instances of paediatric fever, viral infections 
are common within the paediatric oncology population, 
although, due to underlying immunosuppression, may pre-
sent atypically.57 Obtaining a history of contact with infec-
tious individuals and consideration of risk factors for viral 
reactivation (ie allogeneic HSCT) is important and will 
guide diagnostics, preferably molecular based. Empirical 
anti-viral therapy, eg oseltamivir, may be considered in 
children with an influenza-like illness, during periods of 
high population prevalence. Where viral infections are 
suspected, local or international guidelines for manage-
ment should be followed.58–63
The paediatric oncology patients who are most at risk 
of invasive fungal infections (IFI) are those with severe 
and prolonged neutropenia, often those with acute leukae-
mias or receiving HSCT. Additional factors associated 
with IFI include high-dose steroid exposure, acute and 
chronic GvHD and increasing age.64 Particular attention 
should be paid to the clinical history, in particular symp-
toms such as haemoptysis, chest pain, sinus pain, dental 
pain, or skin lesions. Diagnostic markers such as aspergil-
lus antigen, candida antigen, and beta-D-glucan have vari-
able performances and tissue or fluid culture or 
histopathology remains the gold standard.9 Imaging with 
CT chest ± sinuses, ultrasound of the abdomen to exclude 
hepatosplenic lesions and fundoscopy are recommended. 
Empirical treatment with anti-fungal agents is usually con-
sidered in patients at higher risk of IFI between days 3 and 
5 when there has been inadequate response to initial anti-
biotic therapies. However, this may be indicated early in 
very high-risk individuals (eg post-allogeneic HSCT, 
induction therapy for acute leukaemia) or in those with 
symptoms or signs of invasive fungal disease. A review of 
international antifungal treatment guidelines has shown 
that these are varied in quality and recommendations; 
thus, no single national or international guideline can be 
recommended.65 Preemptive antifungal therapy in the face 
of evidence of IFI can be considered as a strategy in place 
of empirical antifungal therapy for children with FN at 
risk of IFI but this approach is currently not widely prac-
tised and is dependent on rapid access to pulmonary CT 
imaging, galactomannan test results and, ideally, the abil-
ity to undertake bronchoscopies with bronchoalveolar 
lavage.66
Impact of Prophylaxis
Antimicrobial selection for FN should also take into con-
sideration concurrent prophylaxis. A systematic review of 
RCTs, including 13 paediatric studies, found fluoroquino-
lone prophylaxis with levofloxacin reduced episodes of 
bacteraemia, fever and FN.67 However there was no dif-
ference in overall mortality and not surprisingly, an 
increase in fluoroquinolone resistance. Prophylaxis guide-
lines for prevention of viral, Pneumocystis jirovecii pneu-
monia, and invasive fungal infections are available and 
beyond the scope of this review.58,65,68–71
Duration of Treatment
The duration of empirical antibiotic therapy remains con-
tentious. An early trial, looking at discontinuation after 
a negative blood culture result compared with continuing 
to count recovery, showed an increased risk of death in the 
early stopping arm.72 This understandably unsettled the 
oncology world, and led to a standard being set of con-
tinuing therapy until the patient was afebrile, free of docu-
mented infection, and had a neutrophil count above 
a specified threshold (often 0.5 x109/L).
While there are robust paediatric data for reduced 
intensity therapy such as oral antibiotics or home-based 
treatments for children with low-risk FN, the specific 
evidence for antibiotic duration in either low- or high- 
risk groups is scant.73 For children with unexplained 
fever, there are generally two approaches to duration 
namely (i) continue until clear signs of marrow recovery 
or (ii) continue until patient is stable and afebrile, irre-
spective of neutrophil count or expected duration of 
neutropenia.15,74,75 Despite the frequency with which FN 
occurs in both adult and paediatric cancer patients, as few 
as eight RCTs have specifically compared these two 
approaches, with only one focusing on high-risk 
patients.76 While children are well represented in these 
studies, there is marked heterogeneity in underlying risk 
status, type of malignancy, definition of clinical failure and 
time of randomisation of included participants and most 
studies were conducted before the year 2000. 
Acknowledging these limitations, a Cochrane review 
found no significant differences in rates of mortality or 
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clinical failures between short or long-course empiric anti-
biotic therapy arms and fewer antibiotic days (by 3–7 
days) in the former.76 Well conducted, prospective trials 
that address antibiotic duration in paediatric patients with 
high-risk FN and that challenge the dogma of continuing 
antibiotics until count recovery are urgently required to 
inform guidelines and clinical practice internationally.
The lack of solid data on when to stop empiric treatment 
mirrors the lack of data supporting the duration of focused 
treatment in identified infections, and the lack of attention to 
this topic in paediatrics generally. Traditional approaches have 
tended to the decimal or the lunar - with treatments being 
a multiple of 7 days, or occasionally 10. For central line 
associated blood stream infections (CLABSIs), the duration 
of therapy may depend on the organism identified and whether 
or not the line remains in situ, guided by local policies. More 
individualised approaches, where the duration of antimicro-
bials is guided by inflammatory or infectious markers, are 
currently under investigation in large trials of immunocompe-
tent children, such as the Batch study in the UK.77
When considering the duration of therapy in FN, both the 
duration of antimicrobials and the duration of hospitalisation 
should be considered. Over the years, various regimes have 
been evaluated, including multiple combinations of loca-
tions (hospital vs home) and route of antibiotic administra-
tion (IV vs oral). A 2016 systematic review of these 
approaches in paediatric patients with low-risk FN found 
that reduced intensity therapies were safe with low rates of 
treatment failure.73 An implementation study from Australia 
similarly showed a significant reduction in hospital length 
(from 4.0 to 1.5 days) with low readmission rates (13%) and 
no adverse outcomes in patients managed on a formal low- 
risk FN program.78 This program is being scaled nationwide 
and has been adapted for use in the UK. Beyond safety, 
home-based FN care has been shown to improve quality of 
life, and reduce healthcare costs, which have been estimated 
at between US $5600 and $11,700 per episode of FN, 
depending on the regimes used for comparison and the 
country in which the research was performed.79–81
Current Best Practice and Future 
Directions in FN
Whilst the above evidence review shows that there are still 
acceptable variations in practice owing to a number of unan-
swered questions about FN management, there is broad 
agreement on the key considerations in FN care. Local cen-
tres should have policies and care pathways for FN manage-
ment that cover the features included in Box 1 and Figure 1. 
Box 2 shows areas for further research in paediatric FN.
Implementing the findings of research in this area has 
met challenges in terms of effecting change in healthcare 
provision. Within the UK, repeated national audits of 
paediatric FN management have found slow changes in 
practice, despite clear national guidelines. Some of these 
issues may relate to previous healthcare professional 
experiences and approaches to risk stratification.82 
However, our experiences of the recent COVID-19 pan-
demic have highlighted the ability to effect rapid imple-
mentation of new practices within FN management, based 
on previous research.83 Thus, future research may focus 
also on the key aspects of implementation science in this 
area.
Conclusion
Although the importance of recognition and careful man-
agement of FN has long been known, modern best practice 
demands prompt recognition, early treatment according to 
risk stratified pathways and attention to the choice of 
empiric antibiotics, role of oral as well as intravenous 
Box 1 Key Features of FN Policies and Guidelines
● Definitions of FN
● Early recognition of FN
● Routine investigations for suspected FN including peripheral blood cultures even if central venous access device present
● Rapid administration of broad-spectrum antibiotics
● Recommended empirical antibiotic regimes
● Risk stratification with defined management pathways for∘ Low-risk episodes of care∘ High-risk episodes of care
● Guidelines on treatment modification including investigation and initiation of antifungal therapy
● Guidelines on duration of treatment by risk group
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antibiotics, place of care and duration of treatment in order 
to give optimal treatment to high-risk patients whilst redu-
cing hospital stay where possible and exercising good 
AMS for all patients. Future research will be important 
to close current gaps in knowledge to further refine current 
treatment protocols and optimise ways of effecting 
Figure 1 Paediatric FN patient pathway and opportunities for intervention and optimisation.74,75
Box 2 Research Gaps in Paediatric FN9,10
- Optimal definition of fever and neutropenia 
- Routine investigations for suspected FN
- Incremental value of a peripheral blood culture in addition to CVC cultures of adequate volume in children with FN
- Utility of new serum biomarkers in children with FN
- Impact of novel biomarkers or point of care tests on antimicrobial selection and duration, including role of PCR for 
respiratory viruses
- Rapid administration of broad-spectrum antibiotics, including optimal TTA
- Which patients with FN will benefit from antibiotic administration within 1 hr
- Recommended empirical antibiotic regimes
- Optimal empirical antibiotics in low-risk FN
- Risk stratification and care pathways
- Developing a validated high-risk stratification schema for paediatric FN
- Implementation and impact (clinical, economic and QoL) of risk stratification pathways
- Optimal type and frequency of re-evaluation for paediatric outpatients with low-risk FN
- Treatment modification
- Optimal frequency of blood culture sampling in persistently febrile paediatric patients with neutropenia who are either 
clinically stable or unstable
- Optimal investigation and treatment for viral and fungal infections in children with FN
- Safety and efficacy of short course antibiotics in children with high-risk FN
- Safety and efficacy of targeted therapy for documented clinical infection
- Should diagnostic and therapeutic approaches differ for prolonged continuous fever vs recurrent fever during FN
Optimal duration of antibiotic therapy
- Optimal treatment duration for microbiologically documented sterile site infections during FN
- Guidelines on duration of treatment by risk group
- Cost-effectiveness of different approaches to managing paediatric FN
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adoption of such improvements. It remains to be seen 
whether rapid diagnostic PCR-based techniques will be 
able to revolutionise pathogen detection, antibiotic selec-
tion and antimicrobial stewardship.
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